Nano-X Imaging Ltd. (NNOX) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Individual inv ...

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential opportunities for traders [1] Premarket Gainers - Brand Engagement Network, Inc. (BNAI) is up 20% at $51.61 [3] - Latham Group, Inc. (SWIM) is up 20% at $7.79 [3] - Evolus, Inc. (EOLS) is up 14% at $4.74 [3] - Edesa Biotech, Inc. (EDSA) is up 11% at $4.86 [3] - 20/20 Biolabs, Inc. (AIDX) is up 11% at $3.28 [3] - DeFi Development Corp. (DFDV) is up 9% at $4.04 [3] - Accel Entertainment, Inc. (ACEL) is up 7% at $11.95 [3] - Solana Company (HSDT) is up 7% at $2.12 [3] - Nano-X Imaging Ltd. (NNOX) is up 6% at $2.76 [3] - Strive Asset Management, LLC (ASST) is up 5% at $8.81 [3] Premarket Losers - Battalion Oil Corporation (BATL) is down 28% at $19.67 [4] - TMD Energy Limited (TMDE) is down 24% at $3.03 [4] - Ascent Industries Co. (ACNT) is down 15% at $14.75 [4] - indie Semiconductor, Inc. (INDI) is down 14% at $2.71 [4] - WEBTOON Entertainment Inc. (WBTN) is down 13% at $9.98 [4] - STAAR Surgical Company (STAA) is down 10% at $17.00 [4] - Indonesia Energy Corporation Limited (INDO) is down 10% at $4.68 [4] - BiomX Inc. (PHGE) is down 7% at $4.52 [4] - Arbutus Biopharma Corporation (ABUS) is down 6% at $4.37 [4] - Global Interactive Technologies, Inc. (GITS) is down 6% at $2.43 [4]

Core Viewpoint - Nanox Imaging Ltd. has signed a distribution agreement with Imperial Imaging Technology to enhance the commercial rollout of its Nanox.ARC system in six southeastern U.S. states, focusing on orthopedic practices and improving access to advanced imaging technology [1][3][4]. Group 1: Distribution Agreement Details - The agreement designates Imperial Imaging as the distributor for the Nanox.ARC system in Georgia, Alabama, Tennessee, North Carolina, South Carolina, and Northern Florida [3]. - Imperial Imaging will handle marketing, sales, customer support, product demonstrations, and clinical evaluations for orthopedic practices [3][4]. Group 2: Market Expansion Strategy - This partnership aligns with Nanox's strategy to build a diverse network of regional distributors with expertise in orthopedic and musculoskeletal practices [4]. - The collaboration aims to expand access to advanced musculoskeletal imaging directly within orthopedic practices, improving patient care and clinical workflows [5][7]. Group 3: Technology and Benefits - The Nanox.ARC system offers 3D imaging capabilities at a lower cost and reduced radiation dose compared to traditional CT scans [2]. - The system is reimbursable under an existing CPT code, eliminating the need for pre-authorization, which can reduce administrative burdens and expedite patient treatment [5][7]. Group 4: Company Background - Imperial Imaging, founded in 2019, has quickly established itself as a leading distributor in the orthopedic community, known for its service and installation expertise [6]. - Nanox aims to drive the transition to preventive healthcare through an integrated medical imaging and healthcare services platform, combining affordable imaging hardware, AI solutions, and cloud-based software [8][9].

Collaboration with Intec SRL drives commercial expansion of 3D medical imaging across a high-growth private healthcare market PETACH TIKVA, Israel, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Nanox Imaging Ltd. (“Nanox”, Nasdaq: NNOX), a leader in innovative medical imaging technology, today announced a distribution agreement with Intec SRL, an Argentina-based medical device distributor with more than 35 years of experience delivering advanced imaging technologies to healthcare providers nationwide. The Nanox.ARC is ...

Core Insights - Nanox Imaging Ltd will showcase its Nanox.ARC digital tomosynthesis system live in Europe for the first time at the European Congress of Radiology (ECR) from March 4-8, 2026, in Vienna, Austria [1][5] Product Overview - The Nanox.ARC is a CE-marked and FDA-cleared multi-source digital tomosynthesis system that enables 3D imaging at a lower cost and significantly reduced radiation dose compared to traditional CT [2][4] - The system's smaller footprint and simplified installation make it suitable for various European healthcare settings, from major medical centers to community clinics [2][4] Demonstrations and Presentations - Live demonstrations of the Nanox.ARC will occur every 30 minutes at booth 425 during the ECR [3][6] - New clinical data on the role of digital tomosynthesis in lung cancer screening will be presented, along with the TAP2D cloud-enabled image enhancement [3][4] - Oral presentations will cover the potential of digital tomosynthesis in lung cancer screening and the role of AI in CT imaging [5][6] AI Solutions - Nanox will showcase its FDA-cleared AI solutions that analyze routine CT scans for chronic disease indicators, including the AI Cardiac solution (HealthCCSng), AI Bone solution (HealthOST), and AI Liver solution (HealthFLD) [4][9] - Two new AI solutions under development for aortic valve calcification and body composition measurement will also be presented [4] Clinical Studies - Poster presentations will feature new data from the ADOPT study conducted in the UK, highlighting the impact of AI-enabled vertebral fracture identification on clinical workflows and treatment recommendations [4][8] Company Vision - Nanox aims to drive the transition to preventive healthcare by providing an integrated medical imaging and healthcare services platform, combining affordable imaging hardware, advanced AI solutions, and cloud-based software [9][10] - The company's vision includes expanding the reach of medical imaging beyond traditional hospital settings to enhance efficiency and support early disease detection [10][12] Ecosystem Components - The Nanox ecosystem includes the Nanox.ARC imaging system, Nanox.AI for AI-based algorithms, Nanox.CLOUD for data management, and Nanox Health IT for healthcare IT solutions [11]

Core Viewpoint - The FDA has granted 510(k) clearance for TAP2D, a new cloud-enabled image enhancement capability for Nanox's digital tomosynthesis systems, marking a significant step in the company's regulatory strategy to establish its systems as primary diagnostic solutions [1][4]. Group 1: Product Development and Features - The TAP2D capability provides radiologists with an additional 2D view generated from digital tomosynthesis scans, enhancing evaluation while maintaining workflow efficiency [2]. - Nanox.ARC and Nanox.ARC X systems utilize advanced 3D imaging technology, offering enhanced diagnostic capabilities at a lower cost and radiation dose compared to traditional systems [3]. - Software upgrades and new capabilities like TAP2D can be added remotely to the Nanox.ARC systems following regulatory clearances [3]. Group 2: Company Vision and Strategy - The company aims to remove the adjunctive use of its systems in the U.S., allowing Nanox.ARC to function as a standalone primary imaging solution, similar to its status in Europe under CE Mark certification [4]. - Nanox is focused on delivering innovations that improve patient care and expand access to high-quality imaging globally [4]. - The company's vision includes expanding medical imaging access beyond traditional hospital settings by providing a seamless solution from scan to interpretation [6]. Group 3: Ecosystem and Services - The Nanox ecosystem includes various components such as Nanox.ARC, Nanox.AI for AI-driven analytics, Nanox.CLOUD for data management, and Nanox Health IT for healthcare IT solutions [7]. - By integrating imaging technology, AI, cloud infrastructure, and clinical expertise, Nanox seeks to lower barriers to adoption and advance preventive care worldwide [8].

Core Insights - Nanox Imaging Ltd. has announced a collaboration with Adriamed to expand its commercial presence in Southeast Europe, particularly in Serbia, Montenegro, and Bosnia and Herzegovina [1][2][4] Group 1: Collaboration Details - Adriamed will serve as the exclusive partner for the Nanox.ARC system in the region, managing marketing, distribution, installation, and support [3] - The Nanox.ARC system utilizes advanced 3D imaging technology to provide enhanced diagnostic capabilities at a lower cost compared to traditional systems, and it holds CE Mark certification for commercialization across Europe [2][3] Group 2: Strategic Goals - The collaboration aims to improve access to cost-effective imaging solutions in underserved communities, thereby enhancing patient care and long-term health outcomes [4][6] - Nanox's strategy focuses on leveraging established regional partners to support market penetration and deliver long-term value to healthcare providers [4][6] Group 3: Company Overview - Nanox is dedicated to transforming healthcare through an integrated medical imaging and healthcare services platform, combining affordable imaging hardware, AI solutions, and cloud-based software [5][6] - The company's vision includes expanding the reach of medical imaging beyond traditional hospital settings, enhancing efficiency in imaging workflows, and supporting early disease detection [6][8]

Summary of Nano-X Imaging Conference Call (December 10, 2025) Company Overview - **Company**: Nano-X Imaging (Ticker: NNOX) - **Industry**: Medical Imaging Technology - **Core Offering**: Advanced diagnostic imaging solutions, including hardware, AI solutions, teleradiology services, and OEM business [2][3][4] Key Points and Arguments Business Model and Technology - **Nano-X Arc**: A digital multi-source 3D tomosynthesis imaging system cleared by the FDA and CE, ready for commercialization in the U.S. and European markets [2][3] - **AI Solutions**: Comprises three main applications for chest, bone, and liver diagnostics, all FDA and CE cleared, aimed at early detection of chronic diseases [3][21] - **Teleradiology Services**: Acquired USARAD in November 2021, enhancing service offerings [3] - **OEM Business**: Involves proprietary tube and chip technology, applicable in medical and other industries [4][23] Recent Developments - **FDA Clearance**: Recently cleared the Arc-X, a second-generation imaging device that is smaller, mobile, and has lower radiation exposure compared to traditional CT machines [11][12] - **Commercial Deployment**: Started commercial deployment of Arc systems in the U.S. and EU, with consistent utilization and clinical adoption reported [6][14] - **Production Plans**: Initial production of Nanox.ARC-X in Israel, with mass production set to commence in Thailand in 2026 [14] Financial Highlights - **Q3 2025 Financials**: - Cash and cash equivalents: $55 million - Shareholders' equity: $156 million - Revenue: $3.5 million - Inventory for pay-per-use model: $49.5 million [24][25] - **Funding**: Recently raised $50 million to support commercialization efforts [24][27] Market Strategy - **Target Markets**: Imaging centers, orthopedic clinics, multispecialty clinics, and urgent care facilities [14] - **Reimbursement Model**: Utilizes CPT code 76100, allowing operators to charge $90-$110 per scan, with a pay-per-use model at $30 per scan [13][17] - **Sales Strategy**: Direct sales force in the U.S. and distributor sales in Europe, focusing on shorter sales cycles due to lower capital investment required [15][17] Clinical and Competitive Advantages - **3D Imaging**: Provides superior imaging capabilities compared to traditional 2D and CT imaging, with reduced radiation exposure [18][19] - **AI Integration**: AI tools enhance diagnostic capabilities and integrate with PACS systems, providing value to radiologists and other medical professionals [21][22] Future Outlook - **Focus on Profitability**: Transitioning from R&D to a product-focused company, with an emphasis on commercialization and shareholder value [27][28] - **AI Expansion**: Plans to accelerate monetization of AI tools and expand business models, indicating potential growth in 2026 [29][30] Additional Important Information - **Regulatory Approvals**: Holds multiple regulatory approvals, including FDA and CE, with installations in Israel and Ghana for clinical data accumulation [18] - **Market Reception**: Positive reception at the RSNA conference, indicating strong interest from prospective clients and distributors [26]

Core Insights - Crude Value Insights provides an investment service and community focused on the oil and natural gas sector, emphasizing cash flow and the companies that generate it, which leads to value and growth prospects with real potential [1] Group 1 - The service includes access to a 50+ stock model account, in-depth cash flow analyses of exploration and production (E&P) firms, and live chat discussions about the sector [1] - Subscribers are offered a two-week free trial to explore the services related to oil and gas investments [2]

Group 1 - Nano-X Imaging reported positive news with a distribution agreement in France, leading to a share price increase of over 9% [1] - The agreement with Althea France allows for the introduction and sale of the Nanox.ARC 3D imaging system in the French market, which is now certified for sale in the EU [2][3] - The CEO emphasized the strategic importance of France and highlighted Althea's expertise in imaging technology as a valuable partnership for growth [3] Group 2 - Nano-X is expanding its European presence, having previously signed similar distribution agreements in the Czech Republic, Greece, and Romania [3][4] - The company's products are positioned as cost-effective alternatives, appealing to healthcare providers with limited budgets [4] - While the impact of the Althea France deal on Nano-X's fundamentals is unclear, it is generally viewed as a positive development [4]